The oncoprotein Stathmin 1 (STMN1) is upregulated in most, if not all, cancers of epithelial cell origin; therefore STMN1 is considered a target for cancer therapy. However its role during metastasis has not been investigated. Here we report for the first time that STMN1 strongly inhibits metastatic behavior in both normal epithelial and cancerous epithelial cells. Initially, lossof-STMN1 compromises cell-cell adhesion. This is followed by epithelial-to-mesenchymal-like transition (EMT), increased cell migration, and metastasis via cooperative activation of p38 and through TGF-ȕ-independent and dependent mechanisms. In contrast, expressing STMN1 restores cell-cell adhesion and reverses the metastatic cascade. Primary prostate epithelial cell cultures from benign to undifferentiated adenocarcinoma clinical biopsies demonstrate that EMT-like cells arise while the cancer is still organ-confined and that their emergence is tumorstage specific. Furthermore, primary EMT-like cells exhibit metastatic behavior both in vitro and in vivo as compared to their non-EMT counterpart. These observations predict that using STMN1 as a generic therapeutic target might accelerate metastasis. Instead, there may be a tumor stage-specific "window-of-opportunity" in which conserving STMN1 expression is required to inhibit emergence of metastatic disease.
.
INTRODUCTION
The oncoprotein stathmin (Stmn1) has been identified in profiling signatures of many cancers ranging from prostate, breast, and colorectal cancers to pheochromocytomas and multiple myeloma (1) (2) (3) (4) (5) . Increased Stmn1 expression correlates with disease progression and poor prognostic outcome (6) . Therefore, it has gained considerable interest as a prognostic marker and potential therapeutic target (7) . STMN1 is a phosphoprotein which regulates cell spindle formation and microtubule dynamics (8) . Dephosphorylation activates STMN1, resulting in microtubule disassembly through the binding of two Į,ȕ-tubulin heterodimers per STMN1 molecule (9) . This step is critical during late metaphase/anaphase where rapid STMN1 dephosphorylation prevents cells from re-entering the cell cycle (10) . In contrast, phosphorylation of STMN1 at serine residues Ser 16 , Ser 25 , Ser 38 , and Ser 63 inactivates STMN1
by reducing its interaction with tubulin, thereby increasing free Į,ȕ-tubulin heterodimers and promoting microtubule assembly (11) (12) (13) . During initiation of mitosis, STMN1 phosphorylation is required for mitotic spindle assembly (14) . Based upon these observations, it is postulated that oncogenesis may arise through constitutive STMN1 phosphorylation or decreased protein expression which deregulates spindle formation and promotes cell cycle progression (14) .
A further mechanism in which STMN1 may be oncogenic is through regulation of cytoskeletal dynamics during EMT and cell migration. In migrating cells, STMN1 is locally inactivated at the leading edge of the cell to allow localized microtubule growth down a gradient of phosphorylated stathmin (15) . Collectively, these observations imply that both promotion of cell cycle progression and EMT requires phosphorylation and subsequent inhibition of STMN1 activity.
STMN1 is phosphorylated in response to p38 and its activity is inhibited by treatment with the p38 inhibitor SB203580 (16, 17) . In MDA-MB-231 cells, p38 signaling enhances cell migration (18) ; whereas a ternary complex formed by Ca 2+ /calmodulin-dependent protein kinase .
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II (CaMK II), Siva1, and STMN1 results in STMN1 phosphorylation at Ser 16 , weakened STMN1-Į-tubulin interactions, and inhibition of EMT and cell migration (19) . Further, p38 promotes EMT through TGF-ȕ-independent and/or TGF-ȕ-dependent signaling (20) (21) (22) . Whether MAP kinase signaling directly down-regulates STMN1 to promote EMT through either TGF-ȕ-dependent orindependent mechanisms remains to be determined.
Based upon these previous studies, it appears that inactivation of STMN1, and not overexpression and/or increased STMN1 activity, is key to promoting oncogenesis and EMT. Zona occludens 1 (ZO-1) is an phosphoprotein expressed on the cytoplasmic membrane surface of intercellular tight junctions of epithelial cells (28) . In control DU-145/pLKO cells, ZO-1 remained arranged in a cortical pattern at cell-cell junctions. In response to decreased STMN1 expression, ZO-1 expression decreased below detection levels (Fig. 1A) . Proteins including Ecadherin form the core of Adherens junctions to initiate and stabilize cell-cell adhesion (29) . In response to depleted STMN1 levels, E-cadherin expression decreased below immunofluorescence detection. In contrast, vimentin expression increased, suggestive of a more mesenchymal phenotype. These changes in protein expression were confirmed by Western blot analysis (Fig. 1B) .
Functional hallmarks of an epithelial to mesenchymal-like transition include increased cell migration, invasion and cell proliferation. To test whether STMN1 modulated cell migration, invasion and/or proliferation, DU-145/shSTMN1 or DU-145/pLKO cells were plated on uncoated polycarbonate membranes and subjected to a serum gradient from serum free medium in the upper chamber to 10% fetal bovine serum (FBS) containing medium in the lower chamber. Both . 9 migration (Fig. 1D ) and invasive activity (Fig. 1E ) in DU-145/shSTMN1 cells increased 3-fold as compared with DU-145/pLKO cells. In contrast, cell proliferation rates in DU-145/shSTMN1 cells decreased (Fig. 1F) .
Taken together, these observations imply that STMN1 is required in maintaining cell-cell adhesion and in suppressing metastatic characteristics.
Loss-of-STMN1 activates p38 MAPK signaling
p38 MAPK activity is reported to promote EMT, cell migration and invasive behavior (22, 30) .
Control DU-145/pLKO cells expressed low basal levels of phospho-p38 ( Fig. 2A) , E-cadherin and ZO-1 was junctional, and vimentin expression remained at basal levels ( To determine whether the phenotypic change was mediated by phospho-p38, cells were treated with the kinase inhibitor SB203580. In DU-145/shSTMN1 cells, SB203580 treatment decreased phospho-p38 expression below detection levels ( Fig. 2A) . Consequently, epithelial cell morphology and cell-cell adhesion were re-established as demonstrated by re-expression and localization of ZO-1 and E-cadherin to cell-cell junctions and a concomitant decrease in vimentin expression to basal levels ( Fig. 2B ). In addition, SB203580 treatment inhibited phospho-p38-mediated migration in DU-145/shSTMN1 cells by 3.5-fold down to basal levels observed in DU-145/pLKO cells (Fig. 2C) . Furthermore, cell invasion ( Fig. 2D ) and cell proliferation ( Fig. 2E ) rates in DU-145/shSTMN1 cells decreased by 15-fold and 2-fold respectively. SB203580 also decreased basal phospho-p38 expression in DU-145/pLKO cells and this was sufficient to decrease invasion and proliferation rates by >8-fold and 2-fold respectively; however basal migration rates were not altered ( Fig. 2A) . By contrast, MMP-2 and MMP-9 expression and activity were significantly induced in DU-145/shSTMN1 cells ( Fig. 2A,F) . MMP-2 proteinase activity appeared predominant, being 3.5-fold greater than that observed for MMP-9 ( Fig. 2F) . In response to SB203580 treatment, MMP-2 and MMP-9 expression were inhibited ( Fig. 2A) and MMP proteinase activity decreased in a dose-dependent manner (Fig. 2F) . Together, these observations imply that down-regulating STMN1 promotes 38 phosphorylation which in turn, induces MMP-2 and MMP-9 expression and activity, resulting in extracellular matrix degradation and increased cell invasion.
Another mechanism by which p38 promotes EMT is through TGF-ȕ-activated Smadindependent signaling (21, 22) . To determine a potential role for TGF-ȕ signaling, DU-145/shSTMN1 and DU-145/pLKO cells were treated with 5ng/ml TGF-ȕ1 for 48 h. EMT morphology was not observed (data not shown) and cell migration and invasion rates were similar in DU-145/shSTMN1 and DU-145/pLKO cells (Fig. 2C, 2D) . Furthermore, SB203580 treatment had no effect, indicating that activation of p38 appeared to be independent of shortterm TGF-ȕ1 treatment.
Increasing STMN1 expression restores a normal epithelial cell phenotype.
The non-transformed normal murine mammary gland (NMuMG) cell line has been extensively used to study EMT mechanisms (20, 33) . One mechanism by which NMuMG cells undergo EMT is through TGF-ȕ-induced activation of p38 MAP kinase (34) (Fig. 3A) . These changes were inhibited by SB203580 treatment. By contrast, NMuMG/pSTMN1 cells retained their cobblestone-like appearance despite TGF-ȕ1 or TGF-ȕ1 plus SB203580 treatment. ZO-1 and E-cadherin remained junctional and ZO-1, E-cadherin and vimentin expression was not altered. Thus, STMN1 expression appeared sufficient to block TGF-ȕ-mediated EMT.
Phospho-p38, MMP-2 and MMP-9 expression were also determined (Fig. 3B, 3C ). In NMuMG/pDream cells, TGF-ȕ1 treatment induced phospho-p38, MMP-2 and MMP-9 expression (Fig. 3B, 3C ) and this could be inhibited with SB203580 treatment. TGF-ȕ1 also increased cell migration (3-fold) and invasion (4-fold) which was inhibited by SB203580 treatment (Fig. 3D, 3E) . While TGF-ȕ1 inhibited endogenous STMN1 expression, SB203580 treatment was sufficient to re-express STMN1 with/or without addition of TGF-ȕ1 (Fig. 3B, 3C ).
Increasing STMN1 expression was also sufficient to decrease cell proliferation (Fig. 3F) .
These observations suggest STMN1 expression is modulated by both TGF-ȕ-dependent and TGF-ȕ-independent activation of p38. Furthermore, restoring STMN1 expression promotes cell-cell adhesion and prevents prometastatic behavior.
Down-regulation of endogenous STMN1 expression by long-term TGF-ȕ1 treatment.
Many epithelial cell lines, including DU-145, do not undergo transition to a mesenchymal phenotype in response to short-term TGF-ȕ1 treatment (20). This suggested that chronic exposure to TGF-ȕ might be required to down-regulate STMN1 expression and induce EMT. To test this hypothesis, native DU-145 cells were treated with 5ng/ml TGF-ȕ1 over a 9 day period. 
Few EMT-like cells were observed at 3 days of TGF-ȕ1 treatment (Fig. 4A) . At this time point, ZO-1 began to decrease while vimentin increased; E-Cadherin remained unchanged (Fig. 4B-D) . On Day 9, most, if not all, cells exhibited morphological changes similar to those observed in DU-145/shSTMN1 cells. STMN1 expression was lost and correspondingly, E-Cadherin and ZO-1 were not observed. Phospho-p38, MMP-2 and MMP-9 increased after 3 days exposure to TGF-ȕ1 and remained high with loss-of-STMN1 expression, suggesting that their expression was regulated, in part, by TGF-ȕ signaling. Taken together, these observations suggest that the TGF-ȕ-mediated decrease in STMN1 expression is through indirect mechanisms.
Decreasing STMN1 activates p38 and cooperates with TGF-ȕ1 to enhance metastasis.
To investigate a potential cooperative interaction between STMN1 and TGF-ȕ signaling, DU-145 cells were transfected with non-targeting siRNA (NTsiRNA) or with STMN1 siRNA (siSTMN1) and treated with increasing concentrations of TGF-ȕ1 (0-5ng/ml). Smad2 and Smad3 were phosphorylated in a dose-dependent manner in DU-145/siSTMN1 cells similar to that observed in DU-145/NTsiRNA cells (Fig. 5A) , albeit at lower levels (Fig. 5B) . To determine the rate of Smad phosphorylation, cells were treated with 5ng/ml TGF-ȕ1 over 8 h. In both cell lines, phospho-Smad2 and phospho-Smad3 increased and reached a peak at 1-2 h (Fig. 5C); however phosphorylation was prolonged in DU-145/siSTMN1 cells (Fig. 5D) . Together, these data suggest that STMN1, in part, regulates the level of Smad2/3 phosphorylation as well as the length of time they are phosphorylated during TGF-ȕ signaling.
The most dramatic response to loss-of-STMN1 was the 6-fold increase in phospho-p38 in untreated DU-145/siSTMN1 cells (Fig. 5C) , suggesting that STMN1 could regulate p38 activity independently of TGF-ȕ. In addition, phospho-p38 expression in DU-145/siSTMN1 cells was greater than that observed in DU-145/NTsiRNA cells with TGF-ȕ1 treatment at all time points tested (Fig. 5D) . These observations provide evidence that STMN1 and TGF-ȕ1 interact cooperatively to regulate p38 MAPK signaling. 
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STMN1 level and tumor-stage determine prometastatic behavior in vitro and in vivo.
To determine whether EMT-like cells were present in clinical prostate cancer (PCa) biopsies, primary epithelial cells were cultured from prostate biopsies ranging from benign prostatic hyperplasia (BPH) to undifferentiated adenocarcinoma (UA) (23) . Primary human prostate epithelial (HPE) cells exhibited typical cobblestone morphology whereas in some cell cultures, EMT-like cells were observed (Fig. 6A) . Few, if any, EMT-like cells were in direct cell-cell contact. As summarized in Immunofluorescence analysis indicated that in UA EMT-like cells, STMN1 along with ZO-1 and E-cadherin expression greatly diminished (Fig. 6A, 6C ) whereas vimentin levels increased (Fig. 6A) . However, UA EMT-like cells continued to express the androgen receptor (AR) and the androgen-regulated protein, prostate specific antigen (PSA) (Fig. 6A) . In addition, they retained expression of other proteins found in mature luminal secretory cells including the prostasome proteins adipophilin and CD59 (24, 25) .
To determine whether UA EMT-like cells exhibited a more invasive phenotype, cell migration, invasion and proliferation assays were performed. Similar to that observed in DU-145/shSTMN1, DU-145/siSTMN1 and NMuMG cells, primary UA EMT-like cells exhibited increased invasion activity (14-fold; Fig. 6E ) and cell proliferation decreased 2-fold (Fig. 6F); however their migration rate resembled that of HPE cells (Fig. 6D) . In contrast, HPE cells (Fig. 6G) .
Furthermore, they expressed AR, PSA, and a second human-specific biomarker hMT (human mitochondria). Since PSA is human-specific, it was used to track the ability of HPE or UA EMTlike cells to migrate out of the tumor graft and into the adjacent kidney tissue. Only PSAproducing cells from UA EMT grafts, but not HPE grafts, infiltrated locally into the kidney parenchyma (Fig. 6H) . Furthermore one overt metastatic lesion to the lung was observed in the UA EMT group (Fig. 6I) and cells within this lesion expressed PSA, confirming that they were of human origin. The observation that only one overt lesion arose in a distant organ implied that while UA EMT cells could metastasize locally, additional events were likely required for a more aggressive metastatic phenotype. 
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DISCUSSION
Our findings, together with previous reports, demonstrate for the first time that STMN1 is a dualfunction protein which is involved in suppressing metastasis and in promoting oncogenesis. In normal NMuMG as well as in DU-146 and primary prostate cancer cells, STMN1 maintains cellcell contacts, inhibits emergence of EMT, and down-regulates expression and activation of MMP-2 and MMP-9. MMPs themselves also carry out dual roles in tumor progression and tumor suppression; however this response appears to be tumor type-specific (35) (36) (37) . Our study indicates that in prostate and breast epithelial cells, MMP-2 and MMP-9 promote tumor progression. As diagrammed in Fig. 7 , there may be a predicative "window-of-opportunity" in which conserving STMN1 expression would inhibit the emergence of prometastatic disease.
Identifying this stage in cancer progression would have major impact on the clinical management of epithelium-derived tumors as to when targeted therapies would be most successful. Thus, the challenge is to conserve non-pathological levels of STMN1 expression in epithelial tumors, since this would be expected to limit metastatic disease, rather than ablating STMN1 which could be expected to lead to metastatic disease.
Prostate cancer is one of the most difficult cancers to diagnose because unlike breast and colon cancer, there is no evidence that PCa progresses through chronological stages from cancer initiation to metastatic disease (38) . Instead, PCa is a multifocal cancer which is evaluated by a sum of the two most prominent histopathological Gleason grades (39). Gleason grades are not arranged in an order of biologic progression. Instead, they are based on physical histopathological criteria that describe the characteristic heterogeneity of morphologies found in PCa and range from 1 through 5 where 1, 2 and 3 are considered to be low to moderate grade and 4 and 5 are considered to be high grade (38, 39) . Our study presents the first biological 
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cells to develop into PSA-producing prostate tumors and their ability to metastasize locally into the surrounding kidney parenchyma in vivo. Interestingly, distal metastasis was limited to the discovery of one overt PSA(+) lesion, suggesting that tissue-derived EMT-like cells require additional events or mutations that promote aggressive spread of the disease. Whether these mutations arise in the tissue-of-origin or at a metastatic site remains to be determined.
A high Gleason score is associated with tumor spread (38) . Down-regulation of STMN1 expression while PCa is still organ-confined could potentially be used as a prognostic biomarker for the emergence of metastatic disease. Whether STMN1 overexpression in metastatic PCa lesions is associated with improved patient survival or alternatively, poor clinical outcome, remains to be determined. Analysis of a large cohort of 546 colorectal cancers (stage I -IV) from two independent prospective cohort studies (the Nurses' Health Study and Health Professionals Follow-up Study) demonstrated that STMN1 overexpression was independently associated with improved patient survival (35) (36) (37) . The outcome of this study suggests that STMN1 overexpression could be a compensatory mechanism by which epithelial cells attempt to maintain cell-cell contact and normal cell function. In this event, it would be of benefit to conserve STMN1 expression and limit metastatic spread through therapeutic management.
Alternatively, other studies have reported that STMN1 overexpression is an independent predictor of poor clinical outcome (35) (36) (37) . While the correlation of STMN1 overexpression with poor prognosis is suggestive of oncogenic activity, this has not been confirmed in translational studies using cells derived from these cancers. Clearly, additional work needs to be done to elucidate the function(s) of STMN1 in both normal and cancer epithelium. The MAPK pathway is one of the Smad-independent mechanisms by which TGF-ȕ regulates cell motility and EMT (34) . Our study shows that loss-of-STMN1 alone is sufficient to activate p38 phosphorylation and MAPK signaling. However, TGF-ȕ1 still increases phosphop38 expression further in a cooperative manner. Therefore, crosstalk between STMN1 and p38 MAPK/TGF-ȕ signaling may emerge as an important regulatory mechanism in conserving an epithelial cell phenotype.
Our study provides a crucial mechanism for STMN1-induced conservation of an epithelial cell phenotype. While STMN1 appears to be an attractive therapeutic target, its dual function as both a metastasis suppressor and oncogene would need to be considered when developing rational therapeutic modalities to treat epithelial cell-derived cancers. 
